

8. The method of Claim 1, wherein the fumonisin analog is selected from the group consisting of Fumonism B<sub>1</sub> and AAL toxin.

17. The method of Claim 9, wherein the fumonisin is selected from the group consisting of Fumonism B<sub>1</sub> and Fumonisin B<sub>2</sub>.

18. The method of Claim 9, wherein the fumonisin analog is selected from the group consisting of Fumonism B<sub>1</sub> and AAL toxin.

*not fumonisin analogue.*  
**REMARKS**  
*no support.*

**Response to Restriction Requirement**

The Examiner has restricted the prosecution of the present application to Group I (claims 1-18), Group II (claims 27 and 28), Group III (claims 29 and 30) or Group IV (claims 37 and 38). Applicants confirm the election of the claims of Group I, without traverse.

The claims of Group I are directed a method of altering the metabolism of sphingolipids in a cell. The Examiner has also requested that the Applicants elect a single disclosed species. Applicants elect the species Fumonisin B<sub>1</sub>.

Respectfully submitted,

*Sherry Knowles*  
Sherry M. Knowles  
Registration No. 33,052

KING & SPALDING  
191 Peachtree Street  
Atlanta, Georgia 30303  
Telephone: 404-572-3541  
Facsimile: 404-572-5145